Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Timothy A. Chan(Cleveland Clinic), Solange Peters(University Hospital of Lausanne)
Cited by 2,867
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k